I picked my 7 companies for the growth side of things. Since I already have a full biotech portfolio, I focused on Tech for this portfolio. I went with a 70% tech and 30% income ratio.
Here are my 7 tech picks: #Fintech 1. $SQ 2. $AFRM #Automation 3. $PATH 4. $PLTR 5. $U #EV 6. $LCID 7. $RIVN
I was going to go with small cap growth stocks, but figured I should probably go with large caps for the stability. I picked my old favorite $CM and $VZ as 2 of them. I will find a 3rd soon for the income side of this portfolio.
I plan to accumulate and average into all the companies I pick by contributing to this portfolio each month. I can adjust and rebalance as I go.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
2/ The Tumor Infiltrating Lymphocytes (TIL) approach is a TCR therapy, but it works differently. They excise the primary tumor from the patient. They isolate the T cell from inside the tumor. Then they genetically identify all the unique antigens for that specific patient.
2/ The T cell receptor recognizes two things. The first is the MHC-I and the other is the actual antigen for its receptor. I spent a lot of time warning you about what could go wrong if you take a T cell from one patient and put it into another without the same MHC-I type.
1/ The insertion of the CAR can be done easily by Lentiviral vectors. This will place the CAR at a place in the genome that is transcriptionally active. The other option requires a much more targeted approach using gene editing.
2/ This approach will place the CAR receptor into the T cell Receptor Alpha Chain locus (TRAC). This achieves two objectives by inserting the CAR while knocking out the TCR.
2/ The ability to take a fibroblast cell and reverse it into a stem cell happened in 2007. A scientist by the name of Shinya Yamanaka and colleagues developed the process to reverse a differentiated cell back into a stem cell.
2/ NK cells work hand in hand with the T cells like the dynamic duo. While T cells look for those peptides being presented by the MHC-I, the NK cells look for the absence of MHC-I. Many infected or cancer cells will reduce or stop producing MHC-I.
2/ Allogeneic CAR-T takes T cells from healthy donors to create the CAR-T therapies. This is done by extracting the T cells from the donor. Then they insert the CAR receptor. They often use gene editing technologies like CRISPR to make additional edits.